Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 43, Issue 4, 2014, Pages 1137-1148

  Lan, Yu Long ^a   Zhao, Jie ^a,b   Li, Shao ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Liaoning Engineering Technology Centre of Target based Nature Products for Prevention and Treatment of Ageing related Neurodegeneration   (China)

Author keywords

Alzheimer's disease; estrogen receptor alpha; neuroprotection; therapy

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AMYLOID BETA PROTEIN; APOPTOSIS SIGNAL REGULATING KINASE 1; CALCIUM ION; CAVEOLIN; CAVEOLIN 1; DAXX PROTEIN; DIARYLPROPIONITRILE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GLUTAMIC ACID; GROWTH FACTOR; HORMONE RECEPTOR AFFECTING AGENT; INSULIN; MEMBRANE PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PYRAZOLE DERIVATIVE; RALOXIFENE; SEX HORMONE; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; VOLTAGE DEPENDENT ANION CHANNEL; ISOPROTEIN; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CAVEOLA; CELL MEMBRANE; COGNITION; ESTROGEN RESPONSIVE ELEMENT; ESTROGEN THERAPY; EXCITOTOXICITY; HORMONAL THERAPY; HUMAN; INTRACELLULAR SIGNALING; MEMORY; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; AGONISTS; ANIMAL; BRAIN; DRUG EFFECTS; GENETICS; METABOLISM; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; ESTROGEN RECEPTOR ALPHA; HUMANS; NEUROPROTECTIVE AGENTS; PROTEIN ISOFORMS;

EID: 84907844226     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141875     Document Type: Review

References (100)

1. Pike CJ, Carroll JC, Rosario ER, BarronAM(2009) Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol 30, 239-258.
2. Rosario ER, Chang L, Head EH, Stanczyk FZ, Pike CJ (2011) Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease. Neurobiol Aging 32, 604-613.
3. Craig MC, Murphy DG (2009) Alzheimer's disease in women. Best Pract Res Clin Obstet Gynaecol 23, 53-61.
4. LeBlanc ES, Neiss MB, Carello PE, Samuels MH, Janowsky JS (2007) Hot flashes and estrogen therapy do not influence cognition in early menopausal women. Menopause 14, 191-202.
5. Prelevic GM, Kocjan T, Markou A (2005) Hormone replacement therapy in postmenopausal women. Minerva Endocrinol 30, 27-36.
6. Drummond ES, Harvey AR, Martins RN (2009) Androgens and Alzheimer's disease. Curr Opin Endocrinol Diabetes Obes 16, 254-259.
7. Webber KM, Casadesus G, Atwood CS, Bowen RL, Perry G, Smith MA (2007) Gonadotropins: A cohesive genderbased etiology of Alzheimer disease. Mol Cell Endocrinol 260-262, 271-275.
8. Meethal SV, Smith MA, Bowen RL, Atwood CS (2005) The gonadotropin connection in Alzheimer's disease. Endocrine 26, 317-325.
9. Palm R, Chang J, Blair J, Garcia-Mesa Y, Lee HG, Castellani RJ, Smith MA, Zhu X, Casadesus G (2014) Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in age-ovariectomized 3xTg AD female mice. J Neurochem 130, 115-125.
10. Wilson AC, Salamat MS, Haasl RJ, Roche KM, Karande A, Meethal SV, Terasawa E, Bowen RL, Atwood CS (2006) Human neurons express type I GnRH receptor and respond to GnRH I by increasing luteinizing hormone expression. J Endocrinol 191, 651-663.
11. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH, Women's Health Initiative Memory, Study (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2947-2958.
12. MakiPM(2006) Hormone therapy and cognitive function: Is there a critical period for benefit? Neuroscience 138, 1027-1030.
13. Sherwin BB (2006) Estrogen and cognitive aging inwomen. Neuroscience 138, 1021-1026.
14. Sherwin BB (2005) Estrogen and memory in women: How can we reconcile the findings? Horm Behav 47, 371-375.
15. Duka T, Tasker R, McGowan JF (2000) The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females. Psychopharmacology 149, 129-139.
16. Maki PM (2012) Minireview: Effects of different HT formulations on cognition. Endocrinology 153, 3564-3570.
17. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J, Women's Health Initiative Memory, Study (2004) Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA291, 2959-2968.
18. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, 3rd Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J, Whims Investigators (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenoposal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 289, 2651-2662.
19. Steingold KA, Cefalu W, Pardridge W, Judd HL, ChaudhuriG( 1986) Enhanced hepatic extraction of estrogens used for replacement therapy. J Clin Endocrinol Metab 62, 761-766.
20. Ansbacher R (2001) The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 184, 255-263.
21. FrickKM(2009) Estrogens and age-related memory decline in rodents: What have we learned and where do we go from here? Horm Behav 55, 2-23.
22. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC, Cache County Memory Study, Investigators (2002) Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA 288, 2123-2129.
23. WhartonW, Baker LD, Gleason CE, Dowling M, Barnet JH, Johnson S, Carlsson C, Craft S, Asthana S (2011) Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausalwomen with Alzheimer's disease: Results of a randomized controlled trial. J Alzheimers Dis 26, 495-505.
24. Naftolin F, MalaspinaD(2007) Estrogen, estrogen treatment and the post-reproductive woman's brain. Maturitas 57, 23-26.
25. Hojo Y, Murakami G, Mukai H, Higo S, Hatanaka Y, Ogiue-Ikeda M, Ishii H, Kimoto T, Kawato S (2008) Estrogen synthesis in the brain-role in synaptic plasticity and memory. Mol Cell Endocrinol 290, 31-43.
26. Cheng D, Liang B, HaoY, ZhouW(2014) Estrogen receptor alpha gene polymorphisms and risk of Alzheimer's disease: Evidence from a meta-analysis. Clin Interv Aging 9, 1031-1038.
27. Hestiantoro A, Swaab DF (2004) Changes in estrogen receptor-alpha and-beta in the infundibular nucleus of the human hypothalamus are related to the occurrence of Alzheimer's disease neuropathology. J Clin Endocrinol Metab 89, 1912-1925.
28. Ishunina TA, Fischer DF, Swaab DF (2007) Estrogen receptor and its splice variants in the hippocampus in aging and Alzheimer's disease. Neurobiol Aging 28, 1670-1681.
29. Prange-Kiel J, Wehrenberg U, Jarry H, Rune GM (2003) Para/autocrine regulation of estrogen receptors in hippocampal neurons. Hippocampus 13, 226-234.
30. Dominguez R, Micevych P (2010) Estradiol rapidly regulates membrane estrogen receptor alpha levels in hypothalamic neurons. J Neurosci 30, 12589-12596.
31. Kelly JF, Bienias JL, Shah A, Meeke KA, Schneider JA, Soriano E, BennettDA(2008) Levels of estrogen receptors and in frontal cortex of patients with Alzheimer's disease: Relationship to Mini-Mental State Examination scores. Curr Alzheimer Res 5, 45-51.
32. Muromoto R (2012) Death domain-associated protein (DAXX)-mediated regulation of transcription and cell death. Yakugaku Zasshi 132, 979-984.
33. Lee YS, Dayma Y, ParkMY, Kim KI, Yoo SE, KimE (2013) Daxx is a key downstream component of receptor interacting protein kinase 3 mediating retinal ischemic cell death. FEBS Lett 587, 266-271.
34. Akterin S, Cowburn RF, Miranda-Vizuete A, Jimenez A, Bogdanovic N, Winblad B, Cedazo-Minguez A (2006) Involvement of glutaredoxin-1 and thioredoxin-1 in betaamyloid toxicity and Alzheimer's disease. Cell Death Differ 13, 1454-1465.
35. Mateos L, Persson T, Katoozi S, Gil-Bea FJ, Cedazo-Minguez A (2012) Estrogen protects against amyloid-beta toxicity by estrogen receptor alpha-mediated inhibition of Daxx translocation. Neurosci Lett 514, 219.
36. HolmgrenA(2000) Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid Redox Signal 2, 811-820.
37. Nilsen J, Brinton RD (2004) Mitochondria as therapeutic targets of estrogen action in the central nervous system. Curr Drug Targets CNS Neurol Disord 3, 297-313.
38. Zhao LZ, Brinton RD (2007) Estrogen receptor alpha and beta differentially regulate intracellular Ca2+ dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons. Brain Res 1172, 48-59.
39. Wu TW, Wang JM, Chen S, Brinton RD (2005) 17Betaestradiol induced Ca2+ influx via L-type calcium channels activates the Src/ERK/cyclic-AMP response element binding protein signal pathway and BCL-2 expression in rat hippocampal neurons: A potential initiation mechanism for estrogen-induced neuroprotection. Neuroscience 135, 59-72.
40. Jelks KB,Wylie R, Floyd CL, McAllister AK,Wise P (2007) Estradiol targets synaptic proteins to induce glutamatergic synapse formation in cultured hippocampal neurons: Critical role of estrogen receptor-alpha. J Neurosci 27, 6903-6913.
41. Xia Y, Xing JZ, Krukoff TL (2009) Neuroprotective effects of R,R-tetrahydrochrysene against glutamate-induced cell death through anti-excitotoxic and antioxidant actions involving estrogen receptor-dependent and-independent pathways. Neuroscience 162, 292-306.
42. Bryant DN, Dorsa DM (2010) Roles of estrogen receptors alpha and beta in sexually dimorphic neuroprotection against glutamate toxicity. Neuroscience 170, 1261-1269.
43. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ (2011) Soluble A beta oligomers inhibit longterm potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containingNMDA receptors. J Neurosci 31, 6627-6638.
44. Palop JJ, Mucke L (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: From synapses toward neural networks. Nat Neurosci 13, 812-818.
45. Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders. Nat Rev Neurosci 11, 682-696.
46. Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA (2009) Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15, 1407-1413.
47. Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Pina-Crespo JC, Lipton SA (2013) Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A 110, E2518-E2527.
48. Han SH, Mook-Jung I (2014) Diverse molecular targets for therapeutic strategies in Alzheimer's disease. J Korean Med Sci 29, 893-902.
49. Morinaga A, Hirohata M, Ono K, Yamada M (2007) Estrogen has anti-amyloidogenic effects on Alzheimer's beta-amyloid fibrils in vitro. Biochem Biophys Res Commun 359, 697-702.
50. Yamin G, Ono K, Inayathullah M, Teplow DB (2008) Amyloid protein assembly as a therapeutic target of Alzheimer's disease. Curr Pharm Des 14, 3231-3246.
51. Yue X, Lu M, Lancaster T, Cao P, Honda S, Staufenbiel M, Harada N, Zhong Z, ShenY, LiR(2005) Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad SciU S A 102, 19198-19203.
52. Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ (2007) Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. Neuroscience 27, 13357-13365.
53. Morinaga A, Ono K, Takasaki J, Ikeda T, Hirohata M, Yamada M (2011) Effects of sex hormones on Alzheimer's disease-associated amyloid oligomer formation in vitro. Exp Neurol 228, 298-302.
54. Fitzpatrick JL, Mize AL, Wade CB, Harris JA, Shapiro RA, Dorsa DM (2002) Estrogen-mediated neuroprotection against beta-amyloid toxicity requires expression of estrogen receptor alpha or beta and activation of the MAPK pathway. J Neurochem 82, 674-682.
55. Meitzen J, Mermelstein PG (2011) Estrogen receptors stimulate brain region specific metabotropic glutamate receptors to rapidly initiate signal transduction pathways. J Chem Neuroanat 42, 236-241.
56. Mermelstein PG (2009) Membrane-localised oestrogen receptor alpha and beta influence neuronal activity through activation of metabotropic glutamate receptors. J Neuroendocrinol 21, 257-262.
57. Lee E, Sidoryk-Wegrzynowicz M, Wang N, Webb A, Son DS, Lee K, Aschner M (2012) GPR30 regulates glutamate transporter GLT-1 expression in rat primary astrocytes. J Biol Chem 287, 26817-26828.
58. Mercier I, Casimiro MC, Zhou. J, Wang C, Plymire C, Bryant KG, Daumer KM, Sotgia F, Bonuccelli G, Witkiewicz AK, Lin J, Tran TH, Milliman J, Frank PG, Jasmin JF, Rui H, Pestell RG, Lisanti MP (2009) Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol 174, 1172-1190.
59. Gaudreault SB, Dea D, Poirier J (2004) Increased caveolin-1 expression in Alzheimer's disease brain. Neurobiol Aging 25, 753-759.
60. Razandi M, Alton G, Pedram A, Ghonshani S,Webb P, Levin ER (2003) Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol 23, 1633-1646.
61. Arvanitis DN, Wang H, Bagshaw RD, Callahan JW, Boggs JM (2004) Membrane-associated estrogen receptor and caveolin-1 are present in central nervous system myelin and oligodendrocyte plasma membranes. J Neurosci Res 75, 603-613.
62. Boulware MI, Kordasiewicz H, Mermelstein PG (2007) Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neurons. J Neurosci 27, 9941-9950.
63. Wang X, Feng S, Zhang H, Wang Y, Cui Y, Wang Z, Liu J, Zou W (2011) RNA inference-mediated caveolin-1 down-regulation decrease estrogen receptor alpha (ER alpha) signaling in human mammary epithelial cells. Mol Biol Rep 38, 761-768.
64. Marin R, Ramirez CM, Gonzalez M, Gonzalez-Munoz E, Zorzano A, Camps M, Alonso R, Diaz M (2007) Voltagedependent anion channel (VDAC) participates in amyloid beta-induced toxicity and interacts with plasma membrane estrogen receptor alpha in septal and hippocampal neurons. Mol Membr Biol 24, 148-160.
65. Elinder F, Akanda N, Tofighi R, Shimizu S, Tsujimoto Y, Orrenius S, Ceccatelli S (2005) Opening of plasma membrane voltage-dependent anion channels (VDAC) precedes caspase activation in neuronal apoptosis induced by toxic stimuli. Cell Death Differ 12, 1134-1140.
66. Herrera JL, Diaz M, Hernandez-Fernaud JR, Salido E, Alonso R, Fernandez C, Morales A, MarinR(2011)Voltagedependent anion channel as a resident protein of lipid rafts: Post-transductional regulation by estrogens and involvement in neuronal preservation against Alzheimer's disease. J Neurochem 116, 820-827.
67. Marin R, Ramirez C, Morales A, Gonzalez M, Alonso R, DiazM(2008) Modulation of A beta-induced neurotoxicity by estrogen receptor alpha and other associated proteins in lipid rafts. Steroids 73, 992-996.
68. Marin R, Diaz M, Alonso R, Sanz A, Arevalo MA, Garcia-Segura LM (2009) Role of estrogen receptor alpha in membrane-initiated signaling in neural cells: Interaction with IGF-1 receptor. J Steroid Biochem Mol Biol 114, 2-7.
69. Kamanga-Sollo E, White ME, Hathaway MR, Chung KY, Johnson BJ, Dayton WR (2008) Roles of IGF-I and the estrogen, androgen and IGF-I receptors in estradiol-17betaand trenbolone acetate-stimulated proliferation of cultured bovine satellite cells. Domest Anim Endocrinol 35, 88-97.
70. Kamanga-Sollo E, White ME, Chung KY, Johnson BJ, Dayton WR (2008) Potential role of G-protein-coupled receptor 30 (GPR30) in estradiol-17beta-stimulated IGF-I mRNA expression in bovine satellite cell cultures. Domest Anim Endocrinol 35, 254-262.
71. Mendez P, Azcoitia I, Garcia-Segura LM (2003) Estrogen receptor alpha forms estrogen-dependent multimolecular complexes with insulin-like growth factor receptor and phosphatidylinositol 3-kinase in the adult rat brain. Brain Res Mol Brain Res 112, 170-176.
72. Kamanga-Sollo E, White ME, Weber WJ, Dayton WR (2013) Role of estrogen receptor (ESR1) and the type 1 insulin-like growth factor receptor (IGFR1) in estradiolstimulated proliferation of cultured bovine satellite cells. Domest Anim Endocrinol 44, 36-45.
73. Chen WF, Zhou LP, Chen L, Wu L, Gao QG, Wong MS (2013) Involvement of IGF-I receptor and estrogen receptor pathways in the protective effects of ginsenoside Rg1 against A25-35-induced toxicity in PC12 cells. Neurochem Int 62, 1065-1071.
74. Wei Z, Mousseau DD, Richardson JS, Dyck LE, Li XM (2003) A typical antipsychotics attenuate neurotoxicity of amyloid (25-35) by modulating Bax and Bcl-X(l/s) expression and localization. J Neurosci Res 74, 942-947.
75. Lebesgue D, Chevaleyre V, Zukin RS, Etgen AM (2009) Estradiol rescues neurons from global ischemia-induced cell death: Multiple cellular pathways of neuroprotection. Steroids 74, 555-561.
76. Broughton BR, Brait VH, Guida E, Lee S, Arumugam TV, Gardiner-Mann CV, Miller AA, Tang SC, Drummond GR, Sobey CG (2013) Stroke increases G protein-coupled estrogen receptor expression in the brain of male but not female mice. Neurosignals 21, 229-239.
77. Shimada K, Kitazato KT, Kinouchi T, Yagi K, Tada Y, Satomi J, KagejiT, Nagahiro S (2011) Activation of estrogen receptor-alpha and of angiotensin-converting enzyme 2 suppresses ischemic brain damage in oophorectomized rats. Hypertension 57, 1161-1166.
78. Hewitt SC, LiY, Li L,Korach KS (2010) Estrogen-mediated regulation of Igf1 transcription and uterine growth involves direct binding of estrogen receptor alpha to estrogenresponsive elements. J Biol Chem 285, 2676-2685.
79. Gottsch ML, Navarro VM, Zhao Z, Glidewell-Kenney C, Weiss J, Jameson JL, Clifton DK, Levine JE, Steiner RA (2009) Regulation of Kiss1 and dynorphin gene expression in the murine brain by classical and nonclassical estrogen receptor pathways. J Neurosci 29, 9390-9395.
80. Micevych P, Dominguez R (2009) Membrane estradiol signaling in the brain. Front Neuroendocrinol 30, 315-327.
81. Hayashi S,YamaguchiY(2008) Estrogen signaling pathway and hormonal therapy. Breast Cancer 15, 256-261.
82. Taylor SE, Martin-Hirsch PL, Martin FL (2010) Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Lett 288, 133-148.
83. Weickert CS, Miranda-Angulo AL, Wong J, Perlman WR, Ward SE, Radhakrishna V, Straub RE, Weinberger DR, Kleinman JE (2008) Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum Mol Genet 17, 2293-2309.
84. Ishunina TA, Swaab DF (2012) Decreased alternative splicing of estrogen receptor-alpha mRNA in the Alzheimer's disease brain. Neurobiol Aging 33, 286-296.e3.
85. Ishunina TA, Fischer DF, Swaab DF (2007) Estrogen receptor alpha and its splice variants in the hippocampus in aging and Alzheimer's disease. Neurobiol Aging 28, 1670-1681.
86. Ishunina TA, Swaab DF (2008) Age-dependent ERalpha MB1splice variant expression in discrete areas of the human brain. Neurobiol Aging 29, 1177-1189.
87. Garcia Pedrero JM, Zuazua P, Martinez-Campa C, Lazo PS, Ramos S (2003) The naturally occurring variant of estrogen receptor (ER) ER Delta E7 suppresses estrogen-dependent transcriptional activation by both wild-type ER alpha and ER beta. Endocrinology 144, 2967-2976.
88. Wong J, Weickert CS (2009) Transcriptional interaction of an estrogen receptor splice variant and ErbB4 suggests convergence in gene susceptibility pathways in schizophrenia. J Biol Chem 284, 18824-18832.
89. Sundermann EE, Maki PM, Bishop JR (2010) A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition. Menopause 17, 874-886.
90. Benvenuti S, Luciani P, Vannelli GB, Gelmini S, Franceschi E, Serio M, Peri A (2005) Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures. J Clin Endocrinol Metab 90, 1775-1782.
91. Luciani P, Deledda C, Rosati F, Benvenuti S, Cellai I, Dichiara F, Morello M,Vannelli GB, Danza G, Serio M, Peri A (2008) Seladin-1 is a fundamental mediator of the neuroprotective effects of estrogen in human neuroblast long-term cell cultures. Endocrinology 149, 4256-4266.
92. Spampinato SF, Molinaro G, Merlo S, Iacovelli L, Caraci F, Battaglia G, Nicoletti F, Bruno V, Sortino MA (2012) Estrogen receptors and type 1 metabotropic glutamate receptors are interdependent in protecting cortical neurons against beta-amyloid toxicity. Mol Pharmacol 81, 12-20.
93. Ramirez CM, Gonzalez M, Diaz M, Alonso R, Ferrer I, Santpere G, Puig B, Meyer G, Marin R (2009) VDAC and ERalpha interaction in caveolae from human cortex is altered in Alzheimer's disease. Mol Cell Neurosci 42, 172-183.
94. Bartella V, De Marco P, Malaguarnera R, Belfiore A, MaggioliniM( 2012) New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cell Signal 24, 1515-1521.
95. Dou JT, Chen M, Dufour F, Alkon DL, Zhao WQ (2005) Insulin receptor signaling in long-term memory consolidation following spatial learning. Learn Mem 12, 646-655.
96. Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV (2001) Insulin promotes rapid delivery of N-methyl-Daspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci U S A 98, 3561-3566.
97. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD, Krohn AJ (2003) Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: Interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28, 809-822.
98. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsa E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 69, 29-38.
99. Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T (2012) Effect of intranasal insulin on cognitive function: A systematic review. J Clin Endocrinol Metab 97, 366-376.
100. Benedict C, Frey WH, 2nd Schioth HB, Schultes B, Born J, Hallschmid M (2011) Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol 46, 112-115.